Johnson & Johnson’s trading activity this week
On October 5, Johnson & Johnson (JNJ) stock opened at $137.43, a decline of ~0.51% compared to its closing price of $139.35 on October 4. Johnson & Johnson stock was trading at its 52-week high of $148.32 on January 17. It’s currently trading ~53.0% higher than its 52-week low of $118.62 reported on May 29.
Over the last week, JNJ stock has risen ~0.82%. JNJ stock has risen ~4.2% over the last month. Year-to-date, JNJ stock has reported a decline of ~0.26%. The one-year stock price return for JNJ stands at ~4.9%. On October 5, Johnson & Johnson stock’s 50-day moving average was $137.60, and its 200-day moving average was $129.10.
Major events that triggered J&J’s recent stock performance
On October 4, Johnson & Johnson’s subsidiary Janssen and Prime Therapeutics entered into a value-based contract for Janssen’s Stelara, which is used for the treatment of psoriasis.
On the same day, Arrowhead Pharmaceuticals entered into a $3.7 billion license agreement for the development and commercialization of a gene-silencing drug for the treatment of Hepatitis B. On October 4, JNJ stock registered a rise of ~0.23%.
On October 2, JNJ stock rose by ~0.57%. On the day, Johnson & Johnson completed the divestiture of its LifeScan division to Platinum Equity. J&J had accepted the acquisition offer by Platinum Equity for J&J’s LifeScan business in June, as reported in An Investor’s Guide: Johnson & Johnson Updates.
On September 26, J&J’s subsidiary Depuy Synthes expanded its spine portfolio with a nerve assessment platform for use during spine surgery.
Be sure to check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look!